Dr. Post, who will also chair the Company’s Research & Development Committee, has extensive biotechnology industry experience including previous global R&D leadership roles at BioMarin and Onyx Pharmaceuticals.Dr. Post’s appointment to the Board is subject to approval by the uniQure shareholders at its Annual General Meeting scheduled for June 17, 2020.